Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi‐Ethnic Study of Atherosclerosis
Journal of the American Heart Association · 06.02.2024 · 13 (3)
DOI: 10.1161/jaha.123.033562 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 06.02.2024. Verfasst von Harpreet S Bhatia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine University of California, San Diego La Jolla CA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Atherosclerosis, Coronary Disease. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Background
Effective therapies for reducing cardiovascular disease (CVD) risk in people with elevated lipoprotein(a) are lacking, especially for primary prevention. Because of the potential association of lipoprotein(a) with thrombosis, we evaluated the relationship between aspirin use and CVD events in people with elevated lipoprotein(a). Methods and Results We used data from the MESA (Multi‐Ethnic Study of Atherosclerosis), a prospective cohort study of individuals free of baseline cardiovascular disease. Due to potential confounding by indication, we matched aspirin users to nonusers using a propensity score based on CVD risk factors. We then evaluated the association between aspirin use and coronary heart disease (CHD) events (CHD death, nonfatal myocardial infarction) stratified by baseline lipoprotein(a) level (threshold of 50 mg/dL) using Cox proportional hazards models with adjustment for CVD risk factors. After propensity matching, the study cohort included 2183 participants, including 1234 (57%) with baseline aspirin use and 423 (19%) with lipoprotein(a) >50 mg/dL. Participants with lipoprotein(a) >50 mg/dL had a higher burden of CVD risk factors, more frequent aspirin use (61.7% versus 55.3%, P =0.02), and higher rate of incident CHD events (13.7% versus 8.9%, P 50 mg/dL and aspirin use had similar CHD risk as those with lipoprotein(a) ≤50 mg/dL regardless of aspirin use.
Conclusions
Aspirin use was associated with a significantly lower risk for CHD events in participants with lipoprotein(a) >50 mg/dL without baseline CVD. The results of this observational propensity‐matched study require confirmation in studies with randomization of aspirin use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Medicine University of California, San Diego La Jolla CA.
- Department of Chemistry and Biochemistry New Mexico State University Las Cruces NM.
- Department of Laboratory Medicine and Pathology University of Minnesota Minneapolis MN.
- Division of Preventive Medicine, Department of Family Medicine University of California, San Diego La Jolla CA.
- Division of Cardiovascular Medicine, Department of Medicine Vanderbilt University Medical Center Nashville TN.
ORCID-Profile: Harpreet S Bhatia, Patrick Trainor, Samantha Carlisle, Michael Y Tsai, Michael H Criqui, Sotirios Tsimikas
Förderung
- NHLBI NIH HHS
Zitieren
APA
Bhatia, H. S., Trainor, P., Carlisle, S., Tsai, M. Y., Criqui, M. H., DeFilippis, A., & Tsimikas, S. (2024). Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi‐Ethnic Study of Atherosclerosis. Journal of the American Heart Association, 13(3). https://doi.org/10.1161/jaha.123.033562
Vancouver
Bhatia HS, Trainor P, Carlisle S, Tsai MY, Criqui MH, DeFilippis A, et al. Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi‐Ethnic Study of Atherosclerosis. Journal of the American Heart Association. 2024;13(3). doi:10.1161/jaha.123.033562
BibTeX
@article{Bhatia2024,
author = {Bhatia, Harpreet S and Trainor, Patrick and Carlisle, Samantha and Tsai, Michael Y and Criqui, Michael H and DeFilippis, Andrew and Tsimikas, Sotirios},
title = {Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi‐Ethnic Study of Atherosclerosis},
journal = {Journal of the American Heart Association},
year = {2024},
volume = {13},
number = {3},
doi = {10.1161/jaha.123.033562}
}
EUVIMED